Past events

Belgian Enterprise Europe Network partner hub.brussels is organizing a virtual brokerage event for companies operating in the ADAS and autonomous vehicles sectors.This is a unique opportunity to match the industry’s future innovation needs with dedicated solution providers.The event will be held on the 14 September 2020 with three timeslots to held the meetings.Attention: below hours are CET.10:00 - 12:00 - B2B meetings13:00 - 15:00 - B2B meetings15:40 - 18:00 - B2B meetingsRegistration deadline: 7 September 2020.Topics to be addressed:Automotive Automotive Cameras LiDARRadar SensorsImage ProcessingComputer VisionIn-cabin MonitoringTesting and ValidationCertification and Standards

Join gamesmatch 2020!For the 8th time the Enterprise Europe Network organises the gamesmatch matching event and offers developers, publishers, investors and many more a unique and efficient way to speed up business meetings!The event will be held virtually from the 25 to 27 August 2020.Target group are game developers, publishers, investors, providers of games-related services, universities and research institutes as well as companies interested in gamification.The event is not open to general business support services, general IT outsourcing companies and students.Registrations are open at:https://gamesmatch2020.b2match.io/

The EU-Japan Centre is currently calling for applications for the next 5-day training missions in Japan.The below-mentioned activity in Japan is financed by the European Commission.As usual, I would be most grateful if you could forward this call for applications to your contacts or colleagues who might be interested in applying."World Class Manufacturing" 5-day training mission in Japan for EU managers working in manufacturing companiesThe 5-day training mission in Japan provides with:- In-depth analysis of Japanese manufacturing methodology- Lectures, seminars and panel discussions, presented by experts from Japanese industry- Company and factory floor (Gemba) visits- Preparation and post-visit reviewsTarget: EU managers working in manufacturing companies (Large and SMEs)No tuition fee for SMEs and the European Commission grants 600 EUR scholarships to participants from SMEs.› WCM I: Training dates: June 2020 - Application deadline in March 2020Application: http://www.eu-japan.eu/events/world-class-manufacturing› WCM II: Training dates: November 2020 - Application deadline in July 2020Application: https://www.eu-japan.eu/events/world-class-manufacturing-november-mission

Within the GlobalStars initiative of EUREKA, Japan will be launching a common call with the Czech Republic, France, Germany, Spain, Canada, Israel and the UK.Starting in early June, companies from Japan and the abovementioned EUREKA member countries are invited to submit joint project proposals in the research and development of innovative products and applications with a strong market potential.The call for proposals will be an open call inviting projects from any sector area except for nuclear technologies and pharmaceutical technologies. Proposing consortia must involve at least one company from Japan and one from the above-mentioned EUREKA countries. For more detailed qualification criteria see the attached pre-announcement text.Call launch: early JuneSubmission deadline: early September.First information on the call in Japanese can be found on the NEDO Website.Companies from the above EUREKA countries are recommend to contact their national funding organisation. The call text will be available on the EUREKA Website after the opening of the call.To inform about the call, the EU-Japan Centre has organised a Webinar on 28 April jointly with EUREKA and NEDO. The recording of the Webinar and the slides including contact details for national funding organisations are available here.The Enterprise Europe Network (EEN) is planning to support partner search for this call throughout the call period from early June to early September.

The 2-week ‘Get Ready for Japan’ scheme offers EU managers the unique opportunity to experience and understand both the cultural and economic elements which define and explain Japan's business and technological achievements. Continuously improved to meet the latest expectations about business in Japan, the Get Ready for Japan provides EU businessmen with a professional Japan-related expertise.It is focused on business management and consists of a combination of lectures, case studies, role plays and company visits. This is designed to help participants become thoroughly informed about the actual conditions of Japanese business through practical analysis and research. Participants will have the opportunity to take part to negotiation role-play exercises and discuss with Japanese managers about decision-making, team management methods in Japan.PARTICIPANT PROFILETypical participants:- have a major role in defining and implementing their companies’ policies vis-à-vis Japan,- are to be transferred to Japan,- come from companies intending to supply Japanese companies,- wish to learn about management practices and technological developments in Japan.ELIGIBILITYThe candidate must:- be a citizen of an EU Member State or of a COSME partnering country;- work for a company that is > 50% EU or COSME partnering country owned;- work for an organisation that is an EU or COSME partnering country juridical person;- be supported by their employer and be able to participate in the entire programme;- have a reasonable command of English;- be a manager or an executive from an industrial company;- have proven experience in industry.PROGRAMME OBJECTIVESThe purpose of the mission in Japan is:- to acquire a broad understanding of the Japanese business environment, business practices and Japanese-style personal communications in order to find ways to do successful business through a partner relationship;- to become aware of the decision-making process inside Japanese companies and therefore gain a better understanding of their negotiation style and hierarchy;- to give the opportunity to reinforce relationships with current Japanese customers and facilitate contacts with future ones.› Get ready for Japan: Training dates: May 2020 - Application deadline:  January 2020Application: https://www.eu-japan.eu/events/get-ready-for-japan-training-programme

Organized by EEN partner WKO AUSSENWIRTSCHAFT AUSTRIA the 2-day international conference will take place virtually on 11-12 March 2021. The main focus of this year's conference is: the factory of tomorrow.The event will be composed of three modules: In the conference module the current trends and innovation leaders in this area will be presented by keynote lectures, in panel discussions and in company testimonials. The exposition module will introduce products, services and projects of innovative Austrian companies and research institutes. And in module 3, the international B2B matchmaking event.Registration free of charge at:https://machinery2021.b2match.io/home

Japanese wine and food importers are invited to a mission in Spain by our Spanish EEN partner Employers’ Federation of La Rioja.The mission will be held on the 26-27 February 2020 in La Rioja, Spain.Registration deadline: 15 December 2019The event will consist of:26th February 2020: B2B meetings. Bilateral business meetings (30’ each one) previously established in individual agendas Logistic ready for wine and products tasting. Importers must attend 16 interwiews, 11 chosen by them and the other 5 by the organizers.27th February 2020: Visits to Rioja companies´premises. Personalised agenda of visits to Rioja producers (according to the selection made by each importer). A maximun of 3 visits per importer.REPRESENTED SECTORS:Enterprises in the Food & Wine Sector from one of the most important Agrofood industrial areas in Spain (Ebro River Valley - La Rioja): DOCa Rioja wine, tinned vegetables (peppers, artichokes, mushrooms, asparagus, etc.), olive oil, cured meats (serrano ham, chorizo, sausages, pork loin…), sauces, ready meal, dairy products, confectionary, snacks & others.The first draft catalogue with Rioja companies profiles will be available from 6th November 2019.WHO CAN PARTICIPATE:Importers/ distributors with purchasing capacity* (legally established since three years at least with a minimum turnover of 500.000 € ). Representatives with capacity of decision in their companies (food chains, supermarkets, purchase agents in the Horeca channel, delicatessen chains of shops and others.*Applications will be evaluated individually by the organizers.CONDITIONS OF PARTICIPATION:Travel expenses to La Rioja, and lodging (3 nights) are 100% free for importers and distributors, they will be covered by the organizers.HOW TO PARTICIPATE:Register on the website platform: https://food-wine-2020.b2match.io - Deadline 15th December.The organizers will then assess the registration, and if positive will take contact with the company to organize the trip.

Within the frame of the Mobile World Congress (https://www.mobileworldcongress.com) the world’s largest gathering for the mobile industry, EEN partner ACCIÓ is organising a brokerage event. The event will be an opportunity to identify potential international partners for future cooperation projects. The participation cost is free but please note that participants will need to purchase an entrance ticket for the MWC fair.Date: 25-27 February 2020Sectors: mobile, telecommunication, ICThttps://mwc2020.b2match.io/

EEN partner Berlin Partner is organizing a matchmaking event within the frame of BIONNALE 2019 conference.Representatives from academia and industry will attend the annual event to identify, engage and enter into strategic relationships. The networking character is one strength of the multi-sessional, international event with more than 900 attendees in the last year. BIONNALE 2019 will again focus on biotechnology, pharmaceuticals and medical technology.Registration deadline: 5 may 2019Registration website: https://bionnale-2019.b2match.io/

The EEN partner the Luxembourg Chamber of Commerce is organizing a B2fair matching event during the Hannover Messe trade fair. The 16th edition of the international brokerage event will take place on 20-24 April 2020. Almost 30,000 business meetings amongst 4,000 companies have been organised in the framework of this brokerage event since 2005. The brokerage event of 2020 at a glance:Five days of business meetingsIndividual intensive business meetings in an exclusive atmosphereA matchmaking lounge located in the centre of the trade fairThe matchmaking event will cover all sectors of Hannover Messe 2019.Participation conditions:Participation fees for the matchmaking event is free of charge for companies that register via the EEN network until 31 January 2020. Please note that a fine of EUR 150 will be invoiced in order to maintain the quality of the event in case companies do not present themselves during the business meetings. After 31 January, the participation fee will be EUR 75.An additional EUR 75 will be charged for every additional participant per company.Registration open at: www.b2fair.com/hannovermesse2020

The EEN partner the Luxembourg Chamber of Commerce is organizing a B2fair matching event during the Hannover Messe trade fair. The 15th edition of the international brokerage event will take place on 1-5 April 2019. Almost 30,000 business meetings amongst 4,000 companies have been organised in the framework of this brokerage event since 2005. The brokerage event of 2019 at a glance:Five days of business meetingsIndividual intensive business meetings in an exclusive atmosphereA matchmaking lounge located in the centre of the trade fairThe matchmaking event will cover all sectors of Hannover Messe 2019.Participation conditions:Participation fees for the matchmaking event is free of charge for companies that register via the EEN network until 15 February 2019. Please note that a fine of EUR 150 will be invoiced in order to maintain the quality of the event in case companies do not present themselves during the business meetings. After 15th February, the participation fee will be EUR 119.00An additional EUR 75 will be charged for every additional participant per company.Registration open at: http://www.b2fair.com/hannovermesse2019

The Life Sciences community in Flanders invites international researchers and companies for a unique conference "Life-on-Chip" aimed to stimulate innovation cross-overs between medical technologies, biotechnologies and regenerative medicine.The Enterprise Europe Network Flanders supports this event and organizes a B2B along this conference. The matchmaking is intended for Business-to-Business, as well as for Science-to-Business.Registration to the conference (€150) is mandatory to be able to attend the B2B session.Registrations at: https://lifeonchip.b2match.io/

Asahi Kasei Pharma to Solicit Proposals for Drug Discovery Research (Jan. 7 to Feb. 22)Asahi Kasei Pharma is publicly calling for new proposals related to drug development research as part its efforts for open innovation, to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes, and enterprises around the world. The application period begins on 3:00 a.m. GMT on January 7, 2019, and ends at 8:00 a.m. GMT on February 22, 2019. Amount of funging ( See below for details)"Research collaboration" category: US$ 50,000/project/year"Research funding" category: US$ 20,000/project/yearAn Overview of Research Topics Sought New drug candidates and drug development technologies in the core research fields of Asahi Kasei PharmaChronic PainAutoimmune DiseasesCritical Care MedicineBones and CartilageNew technologies aimed at addressing the challenges in drug discovery and development at Asahi Kasei PharmaDrug Development Core TechnologyPrediction of Pharmacokinetics and ToxicityDrug Manufacturing TechnologyIdentification of novel drug indicationsA detailed description of each research subject can be found in the following sections.Research Topics SoughtNew drug candidates and drug development technologies in the core research fields of Asahi Kasei PharmaChronic Pain<Drug Candidates>1.1 New drug-target molecules or new drug candidates in the field of pain managementOur scope of indication: Neuropathic pain, osteoarthritic knee pain, postoperative pain, and cancer painOut of our scope: Drug-target molecules and drug candidates that directly act on opioid receptors or inflammatory pathways (e.g., COX)a) Drug targets should ideally be novel molecules, potentially leading to the development of innovative (first-in-class) drugs. We will consider proposals involving multi-target drugs. Combinatorial therapies fall outside the scope of this program announcement.b) Proposals should ideally provide in vivo data. (In vivo studies with relevant knockout mice are also acceptable.) Proposals with evidence from human studies (such as SNP analysis) will also be considered.c) Proposals concerning drug-target molecules that have already been or are being evaluated in Asahi Kasei Pharma may not be considered.<Drug Development Technologies>1.2 New animal models of pain or new techniques for pain measurement that could be useful from the viewpoint of translational researchSpecifically, we are interested in the following:New models of chronic pain or new pain assessment methodologies that utilize non-human primatesNew models of diabetic neuropathy or its bioassay systems that utilize rodents1.3 Simple and reproducible electrophysiological techniques for in vivo evaluation including analysis of drug candidates during non-clinical studies (The analysis must use rodents or higher mammals.)Examples: A technique that can quantify pain-induced neuronal firing (activity) without surgery. (Minor procedures for inserting electrodes into living tissue such as the spinal cord could be acceptable)1.4 Technologies to differentiate human iPS cells into dorsal root ganglia, dorsal-horn neurons, or glial cells (microglia or astrocytes)・ Differentiated cells should possess the functional characteristics of their corresponding primary cultures. The characteristics include expression patterns of marker genes/proteins, profiles of cellular responsiveness, and activities of reference compounds.・ Proposed technologies should allow for the robust and reproducible production of differentiated cells for in vitro screening in multiwell (> 96) plates.1.5 Phenotypic assay systems utilizing neuronal (e.g., dorsal root ganglia or dorsal-horn neurons) or glial (e.g., microglia or astrocytes) cells・ Proposed assay systems should be comprised of pain-related input and output units. Input/output signals related to inflammatory pain (involving, for example, NSAIDs, COX2, or prostaglandins) are outside the scope of this program announcement.・ Proposed assay systems should be suitable for in vitro medium-throughput screening performed in a multiwell (> 96) format.・ When neuronal cells are incorporated into phenotypic assays, one of the following co-culture systems must be used to maintain the cells: 1) dorsal root ganglia and dorsal-horn neurons, or 2) neurons and glia.1.6 Verified biomarkers related to therapeutic effect or disease progression of neuropathic pain in humans (patients) and animal models Autoimmune Diseases<Drug Candidates>2.1 A drug candidate or novel concept/idea that is applicable to the treatment of autoimmune diseases・ Proposals should contain a concept or idea that is expected to be superior to conventional therapy.New drug candidates must be in the stage from basic research to preclinical development.・ Proposed approaches should ideally be applicable to the treatment of rheumatoid arthritis.・ Proposals with specific drug candidates (small molecules, peptides, antibodies, or proteins) are preferred. Critical Care Medicine<Drug Candidates>3.1 New drug candidates for treating sepsis by activating immune responses・ Proposals should ideally include in vivo data obtained from sepsis or infection models. (Laboratory animals injected with LPS will not be considered.)3.2 New drug candidates for acute lung injury (ALI) or acute respiratory distress syndrome (ARDS)Bones and Cartilage<Drug Development Technologies>4.1 New drug discovery technologies which address the issues of human translation in the field of bone regenerative medicine4.1.1. Animal models・ Animal models for evaluating the regenerative effects of drugs used to treat refractory bone diseases, such as osteonecrosis and long bone fractures with non-union or delayed healing4.1.2. Diagnostic modalities for drug development (e.g., biomarkers and imaging technologies for clinical and/or research uses)・ A noninvasive or minimal invasive method to monitor a disease progression or an efficacy of treatment such as a) blood or urine biomarkers b) biomechanical evaluation , and c) imaging technologies or analysis methods (such as CT and MRI).(Ideal methods should be applicable in both nonclinical and clinical settings.)4.2 New technologies for drug discovery that directly address clinical needs in the field of cartilage regenerative medicine4.2.1. In vitro assay systems or animal models・ In vitro assay systems to evaluate regenerative effects of drugs or cells on articular cartilage degeneration or intervertebral disc degeneration: Examples) Co-cultures of graft cells with isolated animal cartilage cells. Cartilage organ culture systems.・ Animal models to evaluate regenerative effects of drugs or cells on articular cartilage degeneration (OA, TA) or intervertebral disc degeneration: Laboratory animals that can potentially be used for these models include rats, miniature pigs, rabbits, and monkeys.(Ideal models should allow for the long-term assessment of human cell-based treatment under immunosuppressive conditions.)4.2.2. Diagnostic modalities for drug development (e.g., biomarkers and imaging technologies)・ Techniques for tracking disease progression or therapeutic response in a noninvasive or minimally invasive manner: a) blood or urine biomarkers, b) biomechanical measurement devices, and c) imaging technologies and image analysis tools (such as CT and MRI).(Ideal methods should be applicable in both nonclinical and clinical settings.New technologies aimed at addressing the challenges in drug discovery and development at Asahi Kasei Pharma Drug Development Core Technologies5.1 Novel techniques for performing structural analysis with crystalline sponges, and new approaches for constructing these molecular cages for the structure determination of low-size molecular (MW ≥500) and middle-size molecular (peptide) compounds・ Proposed crystalline sponges should ideally be able to accept a wide range of guest compounds (e.g., both polar and nonpolar molecules). Alternatively, multiple molecular cages could be built to accommodate a large number of different guest molecules with varying physical properties.5.2 Highly accurate computational method for predicting the acid dissociation constant (pKa) of a small molecule・ Machine learning approaches will not be considered.5.3 A new algorithm for the accurate modeling of membrane proteins (particularly ion channels)・ The performance of the algorithm must have been validated with membrane proteins other than GPCR.5.4 Reaction prediction using a quantum chemistry computational method・ A new methodology for precisely simulating reaction pathways.・ Ideally, proposed approaches should be made readily accessible to chemical scientists.・ AI-based reaction prediction will not be considered.5.5 New descriptors of chemical compounds for the precise modeling of quantitative structure-activity relationships5.6 A new computational approach to predict protein-ligand binding kinetics (kon/koff)5.7 New technology of photoredox reaction for scaling up・ Proposed technologies or devices must be able to scale up for several tens of grams.・ After scaling up the reactions, the yield must be similar to published data.・ The batch reaction systems that can readily be performed in our laboratory will be high priority. The use of a high-cost device (multimillion US dollars) will not be considered.Prediction of Pharmacokinetics and Toxicity6.1 A new technology enabling the effective oral delivery of middle size-molecules including cyclic peptides6.2 In vitro or in silico methodology elucidating the clearance mechanisms including proteolytic elimination and target-mediated drug disposition of middle size-molecules, e.g. cyclic peptides6.3 In silico technologies for predicting on-target toxicities of drug-target proteins・ Can be utilized for the go/no-go decision or prioritization of potential drug-target proteins.・ Applies pathway (or mapping) analysis techniques created based on gene expression, protein-protein interaction, [and/or] text mining.・ Includes the datasets or model built from multiple publicly-available databases.Pharmaceutical Technologies7.1 Novel techniques for stabilizing peptide- and protein-based drugs in aqueous solutionsApplications proposing to use the following approaches will not be considered:・ Lyophilization・ Any procedures that prevent the subcutaneous injection of the drugs・ Covalent modification of the drugs7.2 New technologies for the sustained release of peptides and proteins・ Proposals should ideally include in vivo data.・ Proposed technologies must meet the following three requirements:Controlled release has been shown to continue for at least four weeks.Proposed methods should be clearly superior to existing techniques.Proposed methods should be compatible with subcutaneous administration.Identification of Novel Drug Indications8.1 Discovery of new indications for secreted frizzled-related protein 1 (sFRP1) inhibitors・ Chemical compounds developed at Asahi Kasei Pharma will be provided at no cost. (Their structural information will not be disclosed.)・ The characteristics of our compounds:a) Have approximately 50-fold higher sFRP1-inhibition activities, as compared with the commercially-available tool compound, WAY-316606.b) Can be administered orally.・ High priority will be given to research projects that focus on the field of orthopedics, the medical field where Asahi Kasei Pharma directs its research and development efforts. (Proposals involving osteoporosis research will not be considered.)8.2 Discovery of new indications for transient receptor potential ankyrin 1 (TRPA1) inhibitors in the field of orthopedics・ A chemical compound developed at Asahi Kasei Pharma will be provided at no cost. (Its structural information will not be disclosed.)・ The characteristics of our compound:a) Can inhibit both human and rat TRPA1 with an IC50 value at a few nanomolar.b) Can be administered orally.・ Target indications should belong to the group of orthopedic disorders. (Proposals involving pain will not be considered.)Funding “Research collaboration” categoryOutline:Submitted proposals on the research topics requested by Asahi Kasei Pharma will selected based on a comprehensive evaluation of conformity to the requested topic, originality and usefulness of research content, research plan viability, and conflict with Asahi Kasei Pharma internal projects. We are inviting applications for proposals of new drug candidates and drug development technologies and core technologies for addressing challenges in Asahi Kasei Pharma’s drug development research.Expenses:We are offering up to US$50,000 /project/year (funding will be decided in consultation for each project).Research style and research period:After concluding a research collaboration contract, joint research will be pursued for a period of one year (as a general rule).“Research funding” categoryOutline:Even if a proposal does not meet Asahi Kasei Pharma’s criteria for “research collaboration” category descrived above, if we decide that the proposal is original and potentially useful to the company’s drug development efforts in the future, we may offer financial assistance to support the project.Expenses:Up to US$20,000/project/year. The amount is decided after consultation for each project.Research style and research period:Contracts are different to those of general research collaborations. After a contract is concluded, the supported research is generally pursued for one year.Remarks:Asahi Kasei Pharma will typically have preferential negotiating rights for the research findings. If you obtain useful research findings Asahi Kasei Pharma require at the end of the first year of research, Asahi Kasei Pharma may continue involvement by proposing to extend the research incubation agreement for a second year, or by proposing a research collaboration for the next year. The details of research incubation will be decided in consultation after the selection process, and they will be defined in the contract.“Research under MTA” categoryOutline:Asahi Kasei Pharma provides a compound which has been obtained in the course of our internal past program for free. You use the compound as a tool to explore new target diseases involving the compound.Expenses:Asahi Kasei Pharma does not provide any funds in this category.Research style and period: An MTA contract is concluded, and the research period is generally one year from the time the contract is signed.Remarks:After the end of the research period, if research findings that match the direction of Asahi Kasei Pharma’s R&D efforts are obtained, all rights with regard to the research findings may be basically transferred to Asahi Kasei Pharma at a price.For further information and application form, please contact the EU-Japan Centrem.ashida@eu-japan.eu Date/Time: 3:00 a.m. GMT on January 7 to 8:00 a.m. GMT on February 22, 2019   

Enterprise Europe Network team in Bradford, in partnership with the Science & Media Museum, is organising a B2B matchmaking event alongside the Yorkshire Games Festival on the 7-8 February 2019.The aim of the event is to offer participants a structured way of meeting other event delegates, in order to explore potential collaboration.Up Your Game aims to facilitate collaboration, ideas, innovation and investment in animation, games, motion graphics, VFX, AR and VR.In order to take part in the B2B companies have to purchase passes to the Yorkshire Games Festival. An early bird offer is available until 21st November at £65.00 for two days and £35.00 for one.All the information about the festival and the B2B event, including how it works, is available on the website: https://upyourgame.b2match.io

On the occasion of MEDICA 2018, the global No. 1 meeting place for the medical sector, EEN partner ZENIT GmbH will organise an international Brokerage Event. The aim is to assist enterprises, universities and research institutions in finding partners in Europe for product development, manufacturing and licensing agreements, joint ventures or other types of partnership.Date of event: 12-14 November 2018Registration deadline: 5 November 2018Registration fees200 Euro - Companies / organisations100 Euro - Start-Ups (established on or after 1.1.2016)How to participate:Register at https://medica2018.b2match.io and provide a profile describing either an offer or a request. All the participants’ profiles will be published on the website of the Brokerage Event. Browse the profiles online and book meetings with organisations you are interested in.

EEN partner ACCIÓ is organizing a brokerage event within the frame of the Internet of Things World Congress (http://www.iotsworldcongress.com). The IoT Revolution is challenging companies from all industries to connect their machines, processes, people and products to gain efficiencies, decrease costs, improve operations, increase customer satisfaction and improve work conditions. The event will give participants the opportunity to find international business and technology partners.The Brokerage event is free of chargeParticipants with more than 2 international meetings will receive a discount code for EITHER :A free exhibition visitor pass50% discount on a Congress PassSector: ICTEvent date: 16-17 October 2018

EEN partner ASTER is organising an event in the Life Sciences sector on 10-12 October 2018 in Bologna, Italy.Meet In Italy for Life Sciences 2018 will provide participants with business, partnering and networking opportunities.10th and 11th October: B2B session and Thematic WorkshopsThe first two days will be devoted to bilateral and networking meetings. Participants will also have the possibility of attending thematic workshops. 12th October: Conference The third day will be devoted to an international conference on hot topics in life sciences. Life sciences sector involved:•Pharmaceutical/Nutraceutical•Medical devices •Biology/Biotechnology •IT Applications for Health•Medicine, Human Health and well-being •Related value chain activitiesRegistration deadline 1 October 2018.For more details and to register: https://mit4ls2018.b2match.io/

The Chamber of Commerce and Industry of Pécs-Baranya in collaboration with the Enterprise Europe Network will organize this event for the 3rd time on the 4-5 October 2018 in Pécs, Hungary.The Open4Business Matchmaking Event gives  a perfect possibility for networking with speakers and participants during presentations, panel discussions, B2B matchmaking and many social events.This year a large scale of programmes is available:IT ConferencePécs Design WeekEngineering Clusters MeetingNetworking Events (free of charge for the registered b2b and conference participants)Main focusClustersMachine industryICTCreative industryWomen entrepreneursRegistration deadline: 15 September 2018registration website: https://open4business2018.b2match.io/